BZBingbing Zhang

Bingbing Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bingbing Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Network meta-analysis of metformin, probiotics, krill oil, celecoxib, and glucosamine/chondroitin in the treatment of knee osteoarthritis

    by Keye Chen, Yan Sun, Longkang Cui, Yuchen Zhu, Bingbing Zhang, Haigang Wang

    Purpose: Knee osteoarthritis (KOA) creates a substantial global socioeconomic burden. Celecoxib remains a standard pharmacological treatment, but its long-term safety profile raises concerns. Several adjuvant therapies—probiotics, metformin, krill oil, and glucosamine/chondroitin (CS+GH)—have produced encouraging results in individual trials; however, direct head-to-head comparisons are absent. This network meta-analysis (NMA) compares the efficacy and safety of these five interventions to inform individualized treatment decisions in clinical practice. Methods: RCTs published from database inception through February 2026 were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library. A random-effects NMA was conducted using Stata 18.0 and R (MetaInsight). Continuous outcomes were synthesized as mean differences (MD) and dichotomous safety endpoints as risk ratios (RR). Interventions were ranked by surface under the cumulative ranking curve (SUCRA), and evidence quality was assessed using the GRADE framework. Results: Twenty-three RCTs met the inclusion criteria. No significant network inconsistency ( P > 0.05) or publication bias was detected. For analgesic efficacy, celecoxib ranked highest on VAS pain improvement (MD = −0.48, 95% CI −0.78 to −0.17, SUCRA = 0.93) and WOMAC total scores (SUCRA = 0.912), followed by CS+GH (0.756). Probiotics (0.66) and metformin (0.63) showed potential efficacy, but the final network certainty for most of these auxiliary comparisons was low or very low, mainly due to severe imprecision and the absence of direct head-to-head trials. These SUCRA-based rankings should therefore be interpreted cautiously in clinical settings. On WOMAC subscales, celecoxib was associated with the largest improvements in pain and physical function; krill oil ranked highest on the pain subscale (SUCRA = 0.99), while probiotics and metformin had the most favorable safety profiles (SUCRA = 0.885 and 0.724, respectively). Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261345598 , identifier: CRD420261345598.

  • Open Access

    Effectiveness and safety of probiotics in treating knee osteoarthritis: an updated systematic review and meta-analysis of randomized controlled trials

    by Keye Chen, Yan Sun, Longkang Cui, Yuchen Zhu, Bingbing Zhang, Lianguo Wu

    Knee osteoarthritis (KOA) is a prevalent degenerative joint disease, and gut microbiota dysbiosis in its pathogenesis is a research hotspot. This study performed a traditional meta-analysis to systematically evaluate probiotics’ efficacy (for KOA symptoms, strain-specific superiority) and safety, using RCT data from Chinese and English databases. Stata 17.0 and RevMan 5.4 analyzed outcomes including patient-reported pain (Visual Analog Scale (VAS), WOMAC pain), joint stiffness, function limitation, serum High-sensitivity C-reactive protein (hs-CRP), and safety. Probiotics showed no significant adverse event differences vs. placebo, with no serious safety issues. Results suggest probiotics have potential for KOA, especially Saccharomyces boulardii and LatiLactobacillus sakei LB-P12 . However, small sample sizes and limited studies weaken evidence; further research is needed.

  • Open Access

    Associations between systemic inflammation response index and femur bone mineral density in adults: The NHANES 2005–2010, 2013–2014, and 2017–2018

    by Xiaoang Mm Ye, Xinru Mm Li, Chaojin Mm Zhu, Longkang Cui, Zhe Mm Shen, Kuangying Mm Xu, Gaobo Mm Shen, Lianguo Wu, Bingbing Zhang

    A unique measure of inflammatory evaluation, the systemic inflammation response index (SIRI) may offer useful data for the diagnosis and risk assessment of a number of diseases. The aim of this study was to investigate the relationship between SIRI and femur bone mineral density (BMD) in US adults. The association between SIRI and femur BMD was examined using multivariate logistic regression, sensitivity analysis, and smoothing curve fitting using data from the National Health and Nutrition Examination Survey (NHANES) 2005–2010, 2013–2014, and 2017–2018. Subgroup analysis and interaction tests were employed to examine the population-level stability of this connection. This present study included 18,022 participants older than 20 years from NHANES (2005–2010, 2013–2014, and 2017–2018). The present study showed a negative association between SIRI and femur BMD (including total femur BMD, femoral neck BMD, trochanter BMD, and intertrochanter BMD). In the fully adjusted model, we found a negative association between the SIRI and total femur BMD (Beta = −0.0032, 95% CI: −0.0053 to −0.0012), a negative association between the SIRI and femoral neck BMD (Beta = −0.0025, 95% CI: −0.0045 to −0.0005), a negative association between the SIRI and trochanter BMD (Beta = −0.0032, 95% CI: −0.0050 to −0.0013), a negative association between the SIRI and intertrochanter BMD (Beta = −0.0031, 95% CI: −0.0056 to −0.0007). This negative association was more pronounced in older adults > 65 years of age. In addition, we found a U-shaped association between SIRI and femur BMD by further smoothing curve-fitting methods. SIRI was negatively associated with femur BMD in US adults, and this association was more significant in older adults over 65 years. SIRI may be a useful, convenient, and practical indicator of inflammation. Moreover, older adults with high SIRI levels are likely to have low femur BMD.

  • Open Access

    Magnesium sulphate and sodium bicarbonate as additives for periarticular local infiltration analgesia improve pain management after unicompartmental knee arthroplasty: a prospective, double-blind, randomized controlled trial

    by Yuchen Zhu, Shaoning Shen, Longkang Cui, Lianguo Wu, Bingbing Zhang

    Periarticular local infiltration analgesia (LIA) has become a widely used method for postoperative pain management after unicompartmental knee arthroplasty (UKA). However, the efficacy of using magnesium sulphate or sodium bicarbonate in LIA cocktails during UKA is not yet clear. The present study aimed to evaluate whether the modified LIA has advantages in pain control and joint function recovery after UKA surgery. Sixty-one patients who underwent UKA were enrolled and randomly assigned to receive periarticular infiltration of a modified cocktail (comprising ropivacaine, epinephrine, dexamethasone, magnesium sulphate, and sodium bicarbonate) or a conventional cocktail (comprising ropivacaine, epinephrine, dexamethasone, ketorolac, and morphine). The outcomes included the consumption of patient-controlled intravenous analgesia (PCIA) medication used for postoperative analgesia, pain score, early joint functional recovery, discharge time, and complication rates. In the first 12 h after surgery, the conventional cocktail was not superior to the modified cocktail in terms of visual analogue scale (VAS) scores. However, beginning on the second postoperative day, the analgesic effect was significantly prolonged in the modified group, leading to lower VAS scores and better knee functional recovery. Additionally, patients in the modified group required less pain medication via PCIA, both within the first 24 h and cumulatively up to 48 h after surgery. Both groups had similar rates of complications. The present modification of a conventional cocktail significantly prolonged the analgesic effect and reduced pain medication consumption after UKA surgery, which was associated with better functional recovery in the early postoperative days. Chinese Clinical Trial Registry, ChiCTR2200060500. 21 March 2023.